Agios Pharmaceuticals (AGIO) Change in Account Payables (2012 - 2026)

Agios Pharmaceuticals (AGIO) has 15 years of Change in Account Payables data on file, last reported at $3.1 million in Q2 2026.

• Quarterly Change in Account Payables fell 21.13% year-over-year to $3.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$1.3 million (down 116.87% YoY) and the FY2025 annual result came in at $1.7 million, down 73.55% from the prior year.
• Change in Account Payables advanced to $3.1 million in Q2 2026, from -$5.0 million in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $8.1 million in Q4 2022 to a low of -$9.8 million in Q1 2023.
• A 5-year average of $63166.7 and a median of $337000.0 in 2024 frame the typical range for Change in Account Payables.
• The widest YoY moves for Change in Account Payables: up 436.06% in 2025, down 297.27% in 2025.
• Tracing AGIO's Change in Account Payables over 5 years: stood at $8.1 million in 2022, then plunged by 143.8% to -$3.5 million in 2023, then soared by 78.6% to -$756000.0 in 2024, then plunged by 51.46% to -$1.1 million in 2025, then surged by 369.0% to $3.1 million in 2026.
• The last three Change in Account Payables figures came in at $3.1 million (Q2 2026), -$5.0 million (Q1 2026), and -$1.1 million (Q4 2025), per Business Quant data.